| 產品編號 | bs-20573R |
| 英文名稱 | FREAC3 Rabbit pAb |
| 中文名稱 | 叉頭相關轉錄因子3/FOXC1抗體 |
| 別 名 | ARA; FKH L7; FKHL 7; FKHL7; Forkhead(Drosophila) like 7; Forkhead; forkhead box C1; Forkhead box protein C1; Forkhead drosophila homolog like 7; Forkhead like 7; Forkhead related activator 3; Forkhead related protein FKHL7; Forkhead related transcription factor 3; Forkhead-related protein FKHL7; Forkhead-related transcription factor 3; FOX C1; FOXC 1; FOXC1; FOXC1_HUMAN; FREAC 3; FREAC-3; FREAC3; homolog-like 7; IGDA; IHG 1; IHG1; IRID 1; IRID1; Iridogoniodysgenesis type 1; Myeloid factor delta. |
| 研究領域 | 細胞生物 發(fā)育生物學 轉錄調節(jié)因子 表觀遺傳學 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | Human,Mouse (predicted: Rat,Chicken) |
| 產品應用 | WB=1:500-2000,Flow-Cyt=1ug/Test
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 57 kDa |
| 檢測分子量 | |
| 細胞定位 | 細胞核 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human FREAC3: 201-300/553 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產品介紹 |
Binding of FREAC-3 and FREAC-4 to their cognate sites results in bending of the DNA at an angle of 80-90 degrees.
Involvement in disease; Defects in FOXC1 are the cause of Axenfeld-Rieger syndrome type 3 (RIEG3); also known as Axenfeld-Rieger syndrome (ARS) or Axenfeld syndrome or Axenfeld anomaly. It is characterized by posterior corneal embryotoxon, prominent Schwalbe line and iris adhesion to the Schwalbe line. Other features may be hypertelorism (wide spacing of the eyes), hypoplasia of the malar bones, congenital absence of some teeth and mental retardation. When associated with tooth anomalies, the disorder is known as Rieger syndrome. Glaucoma is a progressive blinding condition that occurs in approximately half of patients with Axenfeld-Rieger malformations. Function: Binding of FREAC-3 and FREAC-4 to their cognate sites results in bending of the DNA at an angle of 80-90 degrees. Subunit: Monomer. Subcellular Location: Nucleus. Tissue Specificity: Expressed in all tissues and cell lines examined. DISEASE: Defects in FOXC1 are the cause of iridogoniodysgenesis anomaly (IGDA) [MIM:601631]. IGDA is an autosomal dominant phenotype characterized by iris hypoplasia, goniodysgenesis, and juvenile glaucoma. Defects in FOXC1 are a cause of Peters anomaly (PAN) [MIM:604229]. Peters anomaly consists of a central corneal leukoma, absence of the posterior corneal stroma and Descemet membrane, and a variable degree of iris and lenticular attachments to the central aspect of the posterior cornea. Similarity: Contains 1 fork-head DNA-binding domain. SWISS: Q12948 Gene ID: 2296 Database links: Entrez Gene: 2296 Human Entrez Gene: 17300 Mouse GenBank: NP_001444 Human Omim: 601090 Human SwissProt: Q12948 Human SwissProt: Q61572 Mouse Unigene: 348883 Human Unigene: 12949 Mouse |
| 產品圖片 |
Sample:
Spleen (Mouse) Lysate at 40 ug
Primary: Anti-FREAC3 (bs-20573R) at 1/300 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 57 kD
Observed band size: 57 kD
Blank control（black line）:Hela.
Primary Antibody (green line): Rabbit Anti-FREAC3 antibody (bs-20573R)
Dilution:1ug/Test;
Secondary Antibody（white blue line）: Goat anti-rabbit IgG-AF488
Dilution: 0.5ug/Test.
Isotype control（orange line）: Normal Rabbit IgG
Protocol
The cells were fixed with 4% PFA (10min at room temperature)and then permeabilized with 90% ice-cold methanol for 20 min at -20℃, The cells were then incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.
|
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
